Clinical stage biopharmaceutical company Race Oncology (ASX: RAC) has appointed Professor Daniel Von Hoff to Race’s Clinical Advisory Board.
Dr Von Hoff is an eminent physician and is the Executive Vice President of the Molecular Medicine Divisions and Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and City of Hope.
He also holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Clinical Research Institute and Professorship of Medicine at the Mayo Clinic.
Dr Von Hoff is a pioneering world leader in translational medicine, accelerating novel drug discoveries from the laboratory to cancer treatments in clinical trials, where he has been involved in over 300 clinical studies.
His major interest is in the development of new anticancer agents, both in the clinic and in the laboratory.
Early in his career, Dr Von Hoff worked with the original developers of bisantrene, Lederle Laboratories, in the design and execution of the clinical studies of bisantrene. He has authored more than 10 publications on bisantrene, including the Phase 3 breast cancer study where bisantrene was compared to doxorubicin and mitoxantrone.
Dr Von Hoff and his colleagues have contributed to the development of many US Food and Drug Administration (FDA) approved pharmaceuticals in routine use, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel, nal-IRI, and pexidartinib.
He has a strong interest in early-phase clinical trials where he and his colleagues are currently focused on developing novel therapies for patients with advanced pancreatic cancer.
Professor Von Hoff has published more than 795 papers, 143 book chapters, over 1195 abstracts with an h-index of 127.
Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO) for his outstanding contributions to cancer research leading to significant improvement in patient care, and he was named one of the ASCO 50 Oncology Luminaries in 2014.
Most recently, he received the American Association of Cancer Research (AACR) Distinguished Public Service Award in recognition of his extraordinary clinical research career and leadership in establishing the AACR/ASCO Methods in Clinical Cancer Research Workshop to educate and train young clinical investigators.
“To attract the interest of a clinical researcher of the international calibre of Professor Von Hoff to counsel Race is humbling. I have no doubt that his expertise and experience will accelerate our clinical and commercial development of RC220 bisantrene,” Race CEO, Dr Daniel Tillett, said.
